Last reviewed · How we verify
NCT04339478: FLUOBCC
Does Parathyroid Autofluorescence Reduces Unintensional Parathyroidectomy During Total Thyroidectomy with Central Lymph Node Compartment Dissection
trial in Thyroid Cancer in 180 participants. Completed in 30 August 2022.
30 March 2022
Quick facts
| Lead sponsor | Aristotle University Of Thessaloniki |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 6 April 2020 |
| Primary completion | 30 March 2022 |
| Estimated completion | 30 August 2022 |
| Sites | 3 locations across Jordan, Turkey (Türkiye), Greece |
Conditions studied
- Thyroid Cancer — all drugs for Thyroid Cancer →
- Thyroidectomy with Central Lymph Node Dissection — all drugs for Thyroidectomy with Central Lymph Node Dissection →
Sponsor
Aristotle University Of Thessaloniki
Who can join
18 and older, any sex, with Thyroid Cancer or Thyroidectomy with Central Lymph Node Dissection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to evaluate the effectiveness of autofluorescence in the intraoperative preservation of parathyroids during total thyroidectomy with central lymph node compartment dissection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04339478
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Cancer
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other Aristotle University Of Thessaloniki trials
Trials by the same sponsor.
- NCT07382479 — NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery · NA · not yet recruiting
- NCT07379905 — MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1) · NA · not yet recruiting
- NCT07335016 — The Role of Follicular Flushing at Oocyte Retrieval · NA · not yet recruiting
- NCT07297121 — Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece. · not yet recruiting
- NCT07210164 — Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04339478 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aristotle University Of Thessaloniki
- Last refreshed: 20 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04339478.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing